Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
1.865
+0.095 (5.37%)
Nov 2, 2026, 2:03 PM EST - Market open
Seres Therapeutics Employees
Seres Therapeutics had 66 employees as of December 31, 2025. The number of employees decreased by 37 or 35.92% compared to the previous year. That makes Seres Therapeutics the 33,789th largest employer in the world and 4,450th in the United States.
Employees
66
Change (1Y)
-37
Growth (1Y)
-35.92%
Revenue / Employee
$28,530
Profits / Employee
-$340,348
Market Cap
18.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66 | -37 | -35.92% |
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| IGC Pharma | 70 |
| Kyntra Bio | 34 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
| Actuate Therapeutics | 12 |
| Cocrystal Pharma | 10 |
MCRB News
- 18 days ago - Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewsWire
- 6 weeks ago - Seres Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics files $300M mixed securities shelf - TheFly
- 2 months ago - Seres Therapeutics Registration statement: Registration filing - Filings
- 2 months ago - Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18) - TheFly
- 2 months ago - Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - GlobeNewsWire